A therapeutics company assessed AML differentiation targets with Polly and its knowledge graph.
The company struggled to consolidate public and internal molecular and clinical data for AML target-indication assessment. Elucidata implemented Polly with automated ingestion and harmonization and knowledge-graph analysis, plus the Data Concierge managed service. The page reports 10 targets assessed in 6 months versus 15-24 months traditionally, a 3x reduction in report generation costs and success probability improved from 1:2000 to 1:5.
Elucidata is a biomedical data company whose Polly platform harmonizes and curates omics and clinical data for AI-driven target discovery.
This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.
Published by Elucidata on its own site — read the original case study on elucidata.io ↗
Related use cases
- 01A diagnostics company used Polly to harmonize EHR, imaging and omics data for hospital-acquired sepsis products.
- 02A biotech built a cross-species knowledge graph on Polly KG and prioritized five targets in six months.
- 03An AI biotech processed bulk RNA-seq on a custom STAR pipeline on Polly for ML training data.
- 04A pharma company used curated single-cell data on Polly to speed target identification in inflammatory disease.
- 05A core facility automated spatial metabolomics analysis with a Polly pipeline.
- 06How Bioventus evolved their commercial strategy with real world data and intelligence